The approval allows the company to market Imfinzi 120 mg ml and 500 mg/10 ml in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi monotherapy as adjuvant treatment post-radical cystectomy. Shares of Astrazeneca Pharma India Ltd ended…
The second order, valued at ₹52.96 crore, has been received from Jhabua Power Limited, a joint venture of NTPC Limited. This involves the operation and maintenance of the boiler, turbine, and generator of a 1×600 MW unit situated in Seoni…
Tech Mahindra is likely to follow in the footsteps of Tata Consultancy Services delivering muted earnings in the first quarter of FY26.
His three-year term begins immediately and will run until August 2028 or further notice, LIC said in an exhange filing.
The company’s revenue from operations surged 22% to ₹957 crore as against ₹783 crore in the corresponding period of the preceding fiscal. The results came after the close of the market hours. Shares of Rallis India Ltd ended at ₹353.80,…
LEQSELVI has shown rapid results in clinical trials, with one-third of patients regaining nearly full scalp hair by Week 24. Additionally, 3% of patients achieved 80% or more scalp coverage in just 8 weeks, addressing a critical unmet need in…
The short-term trend in the Nifty remains weak, and the index may see further range-bound consolidation.
The scope of the contract includes the provision of Kavach on 607 route kilometres of low-density railway track under the jurisdiction of East Central Railway. The project is scheduled for completion by July 14, 2027. Shares of Railtel Corporation of…
For the June quarter, Tata Technologies reported a 10% drop in its net profit to ₹170 crore. During the March quarter, the company had reported a net profit of ₹189 crore.
The retail investors’ portion was subscribed 2.64 times, while the non-institutional investors’ quota was booked 12.28 times. The qualified institutional buyers’ segment saw 9.54 times subscription. The portion reserved for employees was subscribed 2.01 times.